A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 09 May 2014 Biomarkers information updated
- 22 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.